| Transcriptional repressor HIC1 contributes to suppressive function of human induced regulatory T cells U Ullah, SBA Andrabi, SK Tripathi, O Dirasantha, K Kanduri, S Rautio, ... Cell reports 22 (8), 2094-2106, 2018 | 48 | 2018 |
| The L1TD1 protein interactome reveals the importance of post-transcriptional regulation in human pluripotency MR Emani, E Närvä, A Stubb, D Chakroborty, M Viitala, A Rokka, ... Stem cell reports 4 (3), 519-528, 2015 | 40 | 2015 |
| An unbiased in vitro screen for activating epidermal growth factor receptor mutations D Chakroborty, KJ Kurppa, I Paatero, VK Ojala, M Koivu, MZ Tamirat, ... Journal of Biological Chemistry 294 (24), 9377-9389, 2019 | 26 | 2019 |
| Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target J Heliste, A Jokilammi, I Paatero, D Chakroborty, C Stark, T Savunen, ... BMC Cardiovascular Disorders 18, 1-12, 2018 | 15 | 2018 |
| L1TD1 - a prognostic marker for colon cancer D Chakroborty, MR Emani, R Klén, C Böckelman, J Hagström, C Haglund, ... BMC cancer 19, 1-9, 2019 | 14 | 2019 |
| Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin E Narvi, K Vaparanta, A Karrila, D Chakroborty, S Knuutila, A Pulliainen, ... Scientific Reports 8 (1), 16579, 2018 | 14 | 2018 |
| Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases MKA Koivu, D Chakroborty, MZ Tamirat, MS Johnson, KJ Kurppa, ... Molecular cancer therapeutics 20 (3), 564-576, 2021 | 8 | 2021 |
| An unbiased functional genetics screen identifies rare activating ERBB4 mutations D Chakroborty, VK Ojala, AM Knittle, J Drexler, MZ Tamirat, R Ruzicka, ... Cancer Research Communications 2 (1), 10-27, 2022 | 5 | 2022 |
| Trans-activating mutations of the pseudokinase ERBB3 MKA Koivu, D Chakroborty, TT Airenne, MS Johnson, KJ Kurppa, ... Oncogene, 1-13, 2024 | 2 | 2024 |
| DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer M Momeny, M Tienhaara, M Sharma, D Chakroborty, R Varjus, I Takala, ... EMBO Molecular Medicine, 1-27, 2024 | 1 | 2024 |
| Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis M Momeny, M Tienhaara, D Chakroborty, M Sharma, R Varjus, ... bioRxiv, 2023.06. 14.544493, 2023 | | 2023 |
| Trans-activating mutations of the pseudokinase ERBB3 K Elenius, M Koivu, D Chakroborty, T Airenne, M Johnson, K Kurppa | | 2023 |
| Database of recurrent mutations (DORM), a web tool to browse recurrent mutations in cancers D Chakroborty, I Paatero, KJ Kurppa, K Elenius bioRxiv, 2022.11. 21.517363, 2022 | | 2022 |
| 1685P Oncogenic activity of recurrent ERBB4 mutations and their sensitivity to neratinib VK Ojala, A Tuohisto-Kokko, S Ahonen, A Jokilammi, OE Gonzalez, ... Annals of Oncology 33, S1312, 2022 | | 2022 |
| An unbiased in vitro screen for activating ERBB4 mutations D Chakroborty, VK Ojala, AM Knittle, KJ Kurppa, K Elenius Cancer Research 82 (12_Supplement), 153-153, 2022 | | 2022 |
| Screen for actionable ERBB3 mutations MK Koivu, D Chakroborty, KJ Kurppa, K Elenius Cancer Research 82 (12_Supplement), 828-828, 2022 | | 2022 |
| L1td1 as predictive biomarker of colon cancer D Chakroborty, EM Reddy, ELO Laura, R Lahesmaa, A Ristimäki, ... US Patent App. 17/058,926, 2021 | | 2021 |
| Screen for actionable ERBB3 mutations MK Koivu, D Chakroborty, KJ Kurppa, K Elenius Cancer Research 81 (13_Supplement), 2424-2424, 2021 | | 2021 |
| An unbiased in vivo screen for activating EGFR mutations D Chakroborty, KJ Kurppa, K Elenius Cancer Research 81 (13_Supplement), 2299-2299, 2021 | | 2021 |
| Characterizing the oncogenic activity of ERBB4 mutations and their sensitivity to neratinib P Suominen, D Chakroborty, KJ Kurppa, I Diala, LD Eli, AS Lalani, ... Cancer Research 81 (13_Supplement), 2420-2420, 2021 | | 2021 |
Klaus EleniusVerified email at utu.fi
